AlphAIalphai — Financial news for AI agents
manilatimes.netJUN 93 min read$STTKBearishMed

Shattuck Labs, Inc. Announces Proposed Public Offering

Shattuck Labs (NASDAQ: STTK) said it has commenced a proposed public offering of its common stock, or pre-funded warrants in lieu of stock for certain investors. The company expects to grant underwriters a 30-day option to buy up to an additional 15% of shares at the offering price. Terms and size are subject to market conditions.

AI DeskJune 9, 2026
Source · manilatimes.net
AI analysis
Relevance
9/10
Novelty
8/10
Actionability
Med
Sentiment · $STTK
Bearish
Timing
Today’s announcement of a commenced proposed offering (pricing/size subject to market conditions).
Market alignment
Risk-off for the issuer due to dilution overhang; sentiment depends on offering discount and demand once disclosed.
Why this matters for $STTK

Dilutive equity financing risk is the primary near-term driver; traders may price in discount/overhang and watch for offering size/terms.

Relevance context

Shattuck Labs commenced a proposed public offering of common stock and pre-funded warrants, with a 30-day underwriter option for up to 15% more shares.

Price-impact prediction

Likely near-term downside or volatility from dilution/overhang until deal terms and demand are clear.

Background

Shattuck Labs is a clinical-stage biotech developing DR3 blocking antibodies (lead program SL-325).

Why it matters

A commenced public offering introduces dilution/financing overhang; the underwriter option (up to 15% additional shares) can further increase supply if exercised.

Market relevance

This is a direct, issuer-specific financing event that can drive near-term volatility and repricing due to dilution risk.

Market effects

Sector

Adds to the biotech financing tape; may modestly affect sentiment toward clinical-stage names reliant on equity raises.

Regional

No specific regional linkage beyond US-listed biotech capital markets.

Global

Limited; primarily US capital-raising dynamics for a single issuer.

Alternative perspectives

Contrarian view

If the offering is priced tightly and demand is strong, the stock may stabilize quickly and the capital could extend runway for clinical progress.

Overlooked factors

Traders should focus on final offering size, pricing vs. last close, and whether pre-funded warrants signal investor preference for downside protection.

Key entities

  • company
    Shattuck Labs, Inc.

    Clinical-stage biotech that commenced a proposed public offering of common stock and pre-funded warrants.

  • regulator
    SEC

    Registration statement filed Jan. 13, 2026 and declared effective Jan. 21, 2026 for the offering.

  • financial_institutions
    Underwriters (Leerink Partners, J.P. Morgan, Piper Sandler, Cantor)

    Joint bookrunning managers for the proposed offering; underwriters receive a 30-day option for up to 15% more shares.

Read at source← All news

Related articles

JUN 10
$STTKMedAI 8/10

Shattuck Labs Announces Pricing Of 10.88 Mln Shares Public Offering At $4/Shr

Shattuck Labs (STTK) priced its previously announced public offering of 10.88 million shares at $4.00 each, and said it will also issue pre-funded warrants for up to 7.87 million shares at $3.9999 per warrant. The company expects about $75 million in gross proceeds and said the deal should close June 11. Underwriters have a 30-day option for up to 2.81 million additional shares.

rttnews.com2 min
JUN 10
$STTKMedAI 9/10

Shattuck Labs, Inc. Announces Pricing of $75 Million Public Offering

Shattuck Labs (NASDAQ: STTK) priced a public offering of 10,879,376 shares at $4.00 each and pre-funded warrants for up to 7,870,624 shares at $3.9999 each, with a $0.0001 exercise price. Gross proceeds are expected at about $75 million before underwriting costs. The deal is set to close June 11, 2026, with a 30-day option for 2,812,500 additional shares.

manilatimes.net4 min
JUN 10
$STTKMedAI 9/10

Shattuck Labs Announces Pricing Of 10.88 Mln Shares Public Offering At $4/Shr

Shattuck Labs (STTK) priced its previously announced public offering of 10.88 million shares at $4.00 each, and will also issue pre-funded warrants for up to 7.87 million shares at $3.9999 per warrant, according to the company. Gross proceeds are expected at about $75 million before fees. The deal is set to close June 11, with a 30-day option for up to 2.81 million additional shares.

rttnews.com2 min
JUN 5
$STTKMedAI 9/10

Shattuck Labs to Host Investor Call and Webcast on Phase 1 Clinical Data of SL-325, a Potentially First-in-Class DR3 Blocking Antibody, and Pipeline Update on June 8

Shattuck Labs (NASDAQ: STTK) said it will host an investor call and webcast on June 8, 2026 at 8:00 a.m. ET to present Phase 1 clinical data for SL-325, including safety, tolerability, pharmacokinetics, receptor occupancy, pharmacodynamics and immunogenicity, plus a pipeline update. Management including CEO Taylor Schreiber and CFO Andrew Neill will present, followed by Q&A.

manilatimes.net2 min
JUL 11
$BAMed

Boeing invests $1B to expand 737 MAX production in Everett, WA

Boeing said it will invest $1 billion to add a new “North Line” final assembly line for 737 MAX jets at its Everett, Washington facility. The expansion is intended to support demand and a backlog of over 4,300 orders as of May and target 52 aircraft per month. Assembly will use a split process with components built in Renton.

fox13seattle.com3 min